ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Gilead Sciences to Promote Low-Cost HIV Medicine in Developing World

By Chelsea Stevenson Gilead Sciences Inc. (GILD) said it plans to partner with Mylan Inc. (MYL), Ranbaxy Laboratories Ltd. (500359.BY) and Strides Arcolab Ltd. (532531.BY) to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries. The medicine includes single tablet regimens and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under the new agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine as well as funding to reduce overall manufacturing costs. Emtricitabine is marked by Gilead under the name Emtriva and the fixed-dose is available under the name Truvada. But costs are an obstacle for high-volume production. More than 2.7 million patients living with HIV in developing countries are currently receiving a medicine innovated by Gilead and subsequently licensed to Indian generic partners, as part of the company's efforts to increase global access. Strides Arcolab Managing Director Arun Kumar said the partnership will also re-enforce commitments to provide affordable drugs in the tuberculosis and malaria fields. Gilead's second-quarter earnings slid last week as the company posted a double-digit increase in costs, which offset its strong revenue growth. Earlier this year, the company bought Pharmasset Inc. for more than $11 billion, expecting the company to help accelerate the development of treatments for hepatitis C. Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
12/08/201608:11:00Gilead Submits New Drug Application to U.S. Food & Drug Administration...
12/05/201612:55:10Statement of Changes in Beneficial Ownership (4)
11/29/201614:46:04Statement of Changes in Beneficial Ownership (4)
11/29/201614:13:36Statement of Changes in Beneficial Ownership (4)
11/28/201608:30:00Innovative Clinical Trial Implementation and Manufacturing Capacity...
11/23/201608:13:00Gilead Sciences Canada, Inc., se voit décerner le prestigieux...
11/23/201608:10:00Gilead Sciences Canada, Inc., is awarded prestigious Prix Galien...
11/22/201614:46:39Statement of Changes in Beneficial Ownership (4)
11/21/201613:10:15Initial Statement of Beneficial Ownership (3)
11/16/201617:00:00Gilead Sciences Announces Promotion of James R. Meyers to Executive...
11/16/201616:15:00Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating...
11/15/201617:00:00Gilead Sciences to Present at the Annual Piper Jaffray Healthcare...
11/14/201616:30:00Medicare Identifies Which Prescription Drugs Were Costliest in...
11/14/201616:30:00Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis...
11/14/201613:04:40Statement of Changes in Beneficial Ownership (4)
11/11/201607:25:00European CHMP Adopts Positive Opinion for Gilead’s Vemlidy® (T...
11/10/201613:06:00U.S. Food & Drug Administration Approves Gilead’s Vemlidy® (T...
11/07/201617:32:13Quarterly Report (10-q)
11/03/201618:11:28Statement of Changes in Beneficial Ownership (4)
11/02/201609:52:00U.S. Hot Stocks: Hot Stocks to Watch

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US